List of Excipients in Branded Drug LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

« Back to Dashboard

Generic Drugs Containing LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	losartan potassium and hydrochlorothiazide	0093-7367	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	losartan potassium and hydrochlorothiazide	0093-7367	D&C YELLOW NO. 10 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	losartan potassium and hydrochlorothiazide	0093-7367	FD&C BLUE NO. 1 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	losartan potassium and hydrochlorothiazide	0093-7367	LACTOSE MONOHYDRATE
Teva Pharmaceuticals USA Inc	losartan potassium and hydrochlorothiazide	0093-7367	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE?

# Of NDCs	Excipient
1	ACID YELLOW 3
4	ALUMINUM OXIDE
21	ANHYDROUS LACTOSE
1	CARNAUBA WAX
122	CELLULOSE, MICROCRYSTALLINE

Losartan Potassium and Hydrochlorothiazide Excipient Strategy and Commercial Opportunities

Last updated: October 14, 2026

Losartan potassium and hydrochlorothiazide is a mature, multisource antihypertensive combination with limited core patent protection and intense price competition. Commercial value is concentrated in manufacturing efficiency, supply reliability, dosage-form differentiation, excipient control, and access to markets where fixed-dose combination penetration remains low.

The principal marketed strengths are 50 mg/12.5 mg, 100 mg/12.5 mg, and 100 mg/25 mg immediate-release tablets. The original brand, Hyzaar, was developed by Merck and approved by the FDA in 1995. The product has no biosimilar pathway because it is a chemically synthesized small molecule. Generic manufacturers generally use the abbreviated new drug application, or ANDA, pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.[1][2]

What is the commercial profile of losartan potassium and hydrochlorothiazide?

Losartan potassium and hydrochlorothiazide combines an angiotensin II receptor blocker with a thiazide diuretic. Losartan reduces angiotensin II-mediated vasoconstriction, while hydrochlorothiazide increases renal sodium and water excretion.

Attribute	Product profile
Active ingredients	Losartan potassium and hydrochlorothiazide
Original brand	Hyzaar
Reference sponsor	Merck
Dosage form	Immediate-release oral tablet
Principal strengths	50/12.5 mg, 100/12.5 mg, 100/25 mg
Regulatory pathway for generics	ANDA under section 505(j)
Therapeutic area	Hypertension
Biosimilar exposure	None
Core patent position	Mature and largely expired in major markets
Primary commercial pressure	Generic price competition
Main differentiation levers	Cost, supply, packaging, tolerability, dosage-form convenience, market access

Fixed-dose combinations can improve adherence by replacing two tablets with one. The commercial opportunity is strongest in markets with high hypertension prevalence, fragmented prescribing, and limited availability of combination products.

The product also benefits from broad prescriber familiarity. Losartan is one of the most commonly used angiotensin receptor blockers, while hydrochlorothiazide has a long history of use in hypertension. That familiarity reduces clinical adoption risk for generic versions.

What patents protect losartan potassium and hydrochlorothiazide?

The original composition-of-matter and combination-product patent estate is no longer the principal barrier to generic entry in the United States. Hyzaar and equivalent products have been exposed to generic competition for many years.

The relevant patent categories historically included:

1. Losartan active-ingredient patents.
2. Hydrochlorothiazide-related product and formulation claims.
3. Fixed-dose combination compositions.
4. Tablet manufacturing and formulation claims.
5. Method-of-use claims for hypertension and related cardiovascular conditions.

The strongest historical patent protection covered losartan itself and the combination of losartan with a diuretic. Those rights have expired or ceased to provide meaningful market exclusivity in the principal generic markets. Any remaining patent issue is more likely to involve a particular formulation, manufacturing process, or jurisdiction than the basic combination.

When did losartan and Hyzaar lose exclusivity?

Hyzaar lost practical market exclusivity after generic losartan and losartan/hydrochlorothiazide products entered the U.S. market. The relevant exclusivity period is therefore historical rather than a future launch event.

Exclusivity category	Commercial status
Losartan compound protection	Expired
Fixed-dose losartan/hydrochlorothiazide protection	Expired or commercially nonblocking in major generic markets
Brand market exclusivity	Expired
Generic competition	Established
Future pediatric or orphan exclusivity	Not a current commercial factor
Biosimilar exclusivity	Not applicable

Exact patent expiration dates can differ by patent family, filing date, patent-term adjustment, patent-term extension, and jurisdiction. FDA Orange Book listings and patent certifications remain relevant for a specific ANDA, but the mature status of the product means that an entrant ordinarily competes on cost and execution rather than waiting for a future primary patent expiry.[1]

What is the FDA regulatory status and Orange Book position?

Losartan potassium and hydrochlorothiazide is an FDA-approved prescription tablet product. The reference product is Hyzaar, and multiple approved generic products are listed in FDA drug databases.

An ANDA applicant must generally establish:

• The same active ingredients as the reference product.
• The same strength and dosage form.
• The same route of administration.
• Pharmaceutical equivalence.
• Bioequivalence.
• Acceptable stability and manufacturing controls.
• Compliance with current good manufacturing practice requirements.

The FDA Orange Book is the controlling source for listed patents, therapeutic-equivalence codes, reference products, and exclusivity information. For a generic applicant, the relevant legal pathway is typically Paragraph III or Paragraph IV certification, depending on whether any listed patents remain relevant to the targeted product.[1]

Are Paragraph IV challenges still commercially important?

Paragraph IV litigation was more important during the original generic launch period than it is for current entrants. Because the product is mature, a new applicant is more likely to encounter expired patents, absent listed patents, or a low-value patent challenge than a major litigation-driven launch delay.

Paragraph IV risk can still arise when:

• A new formulation is listed.
• A specific strength has a later patent.
• A manufacturer targets a modified dosage form.
• A patent owner asserts a process or formulation patent.
• A jurisdiction maintains a different patent position from the United States.

For a conventional immediate-release tablet using established excipients, patent risk is generally lower than regulatory, supply-chain, and price risk.

What excipients are used in losartan potassium and hydrochlorothiazide tablets?

Excipients vary by manufacturer and strength. Typical immediate-release formulations use a compactible filler, disintegrant, glidant, lubricant, and film-coating system.

Common excipient classes include:

Excipient class	Typical examples	Primary function
Diluent or filler	Microcrystalline cellulose, lactose monohydrate, dibasic calcium phosphate	Tablet mass and compressibility
Disintegrant	Pregelatinized starch, crospovidone, sodium starch glycolate	Tablet breakup after ingestion
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Granule and tablet strength
Glidant	Colloidal silicon dioxide	Powder flow
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Film former	Hypromellose, hydroxypropyl cellulose	Coating structure
Plasticizer	Polyethylene glycol	Coating flexibility
Opacifier	Titanium dioxide	Appearance and light protection
Colorant	Iron oxides or approved lake dyes	Strength identification
Anti-tacking agent	Talc	Coating-process control

The formulation must accommodate two active ingredients with different dose levels and different physical properties. Losartan potassium is present at a substantially higher mass than hydrochlorothiazide in the 100/12.5 mg and 100/25 mg strengths. Uniform distribution of the lower-dose hydrochlorothiazide component is therefore a central process and formulation issue.

Inactive ingredients for FDA-approved products should be checked against the FDA Inactive Ingredient Database, product labeling, and the specific reference-product formulation.[3][4]

How should manufacturers design an excipient strategy?

The best commercial strategy is usually a robust, low-cost immediate-release formulation rather than a heavily differentiated platform. The formulation should prioritize content uniformity, rapid dissolution, stability, and manufacturability.

Control low-dose hydrochlorothiazide distribution

Hydrochlorothiazide represents a relatively small fraction of the total tablet mass. Direct blending can create segregation risk, especially when particle-size distributions, density, or electrostatic behavior differ between the two active ingredients and the excipient blend.

Practical options include:

• Ordered mixing.
• Wet granulation.
• Dry granulation.
• Separate premixes for the lower-dose component.
• Particle-size engineering.
• Controlled addition of glidant and lubricant.
• In-process blend uniformity testing.

Wet granulation can improve content uniformity and compressibility but may increase process complexity and thermal or moisture exposure. Direct compression can reduce cost and processing time but requires strong control of particle size, flow, segregation, and compression behavior.

Manage losartan stability

Losartan potassium formulations must be assessed for degradation under heat, humidity, light, and oxygen exposure. Excipient selection can affect water activity, microenvironmental pH, tablet hardness, dissolution, and impurity formation.

Key controls include:

• Low-moisture excipient grades where justified.
• Packaging with adequate moisture protection.
• Compatibility screening for lactose, starches, lubricants, and coating components.
• Stability testing at long-term and accelerated conditions.
• Control of residual moisture after granulation.
• Evaluation of light exposure during manufacturing and storage.

A formulation that uses inexpensive excipients but requires high-barrier packaging may not have the lowest total cost. Packaging and stability should be optimized together.

Optimize dissolution across all three strengths

A single formulation platform may support 50/12.5 mg, 100/12.5 mg, and 100/25 mg strengths, but proportional scaling is not always appropriate. Changes in active-to-excipient ratio can alter hardness, disintegration, dissolution, and blend uniformity.

A development program should compare:

• Tablet weight by strength.
• Compression force.
• Disintegration time.
• Dissolution profiles.
• Assay and content uniformity.
• Stability impurity profile.
• Film-coating weight gain.
• Tablet friability.

The use of a common platform can reduce manufacturing complexity, but separate process parameters may be required for the lower-dose hydrochlorothiazide strength.

What formulation patents protect losartan and hydrochlorothiazide products?

For a conventional tablet, the commercial value of formulation patents is limited unless the formulation produces a measurable regulatory or clinical advantage. Potential patentable areas include:

• Improved dissolution or bioavailability.
• Moisture-stable compositions.
• Reduced impurity formation.
• Controlled particle-size distributions.
• Segregation-resistant blends.
• Specific granulation processes.
• Taste-masked or orally disintegrating dosage forms.
• Sprinkle formulations.
• Modified-release systems.
• Fixed-dose combinations with additional antihypertensive agents.

A formulation patent must be evaluated against public prior art covering losartan, hydrochlorothiazide, direct compression, wet granulation, tablet coatings, and fixed-dose antihypertensive combinations. Broad claims based only on routine excipient substitution are likely to face validity and obviousness challenges.

The more defensible strategy is to generate comparative data showing an unexpected technical effect, such as materially improved stability, dissolution, content uniformity, or manufacturability.

What commercial opportunities exist for excipient innovation?

Low-cost generic platform

The largest opportunity is a reliable, scalable tablet platform with low manufacturing cost. Candidate advantages include:

• Direct compression where blend uniformity is acceptable.
• Reduced coating weight.
• Lower lubricant concentration.
• Fewer excipient grades.
• Common tooling across strengths.
• Shorter processing time.
• Reduced reject rates.

This strategy targets large-volume tenders and pharmacy benefit managers. The product is unlikely to command a premium, so even small reductions in yield loss or cycle time can affect margins.

Lactose-free or low-lactose products

Some manufacturers may seek formulations without lactose because of patient preference, excipient restrictions, or portfolio standardization. Microcrystalline cellulose, mannitol, dibasic calcium phosphate, and selected starch systems can support alternative formulations.

A lactose-free product is not automatically clinically superior. Its value depends on distribution channels, market requirements, and whether the manufacturer can avoid higher cost or poorer tablet performance.

Sodium-reduced or excipient-conscious positioning

Patients with hypertension often receive counseling on sodium reduction. The active product does not normally require a high-sodium excipient system, but excipient declarations can matter in institutional procurement and patient information programs.

The commercial claim must be based on the complete formulation and local labeling rules. It should not imply that the medicine itself is appropriate for all patients with sodium-sensitive conditions.

Orally disintegrating and sprinkle formulations

An orally disintegrating tablet could target patients with dysphagia, older adults, or patients with difficulty swallowing conventional tablets. A sprinkle formulation could support administration through selected feeding tubes or soft food.

These products would face higher development and regulatory risk than a conventional tablet. Critical issues include:

• Dose uniformity in each unit.
• Chemical stability after dispersion.
• Administration-device compatibility.
• Tube adsorption or clogging.
• Palatability.
• Food and beverage compatibility.
• New bioequivalence requirements.

The opportunity is real but narrower than the standard tablet market.

Pediatric and geriatric dosage flexibility

Losartan is used in pediatric hypertension in certain circumstances, but a losartan/hydrochlorothiazide fixed-dose product may not be the preferred initial treatment for children. A liquid or dispersible formulation would require careful evaluation of dose flexibility, stability, palatability, and labeling.

For older adults, a scored tablet or lower-dose combination may offer greater utility than a novel excipient system. Tablet splitting, however, requires demonstrated dose uniformity and appropriate product design.

How does losartan/hydrochlorothiazide compare with competing antihypertensive combinations?

The product competes with combinations based on valsartan, irbesartan, olmesartan, candesartan, amlodipine, chlorthalidone, and other diuretics.

Combination category	Competitive strength	Excipient opportunity
Losartan/hydrochlorothiazide	Low-cost, familiar, broad generic availability	Manufacturing efficiency and adherence packaging
Valsartan/hydrochlorothiazide	Strong brand and generic presence	Stability and supply reliability
Amlodipine/ARB	Avoids diuretic-related electrolyte effects for some patients	Smaller tablets and patient-friendly dosage forms
ARB/chlorthalidone	Longer-acting diuretic profile	Differentiated clinical positioning, subject to evidence
Single-agent ARB	Simpler titration	Combination-product adherence advantage

Losartan/hydrochlorothiazide has a cost advantage but less formulation differentiation than newer or more complex combinations. A manufacturer should avoid assuming that a new excipient system alone will shift prescribing. Commercial success depends on demonstrated usability, procurement economics, or a specific access need.

Which companies are challenging or competing with Hyzaar?

Competition comes primarily from generic manufacturers and contract manufacturers rather than from biosimilar developers. Generic losartan/hydrochlorothiazide products have been marketed by multiple companies, including large multinational generic firms and regional suppliers.

The competitive landscape is determined by:

• FDA approval status.
• Therapeutic-equivalence designation.
• Supply continuity.
• Pricing and rebate structure.
• API sourcing.
• Manufacturing location.
• Product recalls or shortage history.
• Tender participation.
• Packaging and private-label capabilities.

Because the active ingredients are mature, a new entrant needs either a lower cost base, dependable supply, a differentiated dosage form, or geographic access to a market with limited competition.

What manufacturing and intellectual-property barriers remain?

The largest barriers are operational rather than basic composition-of-matter patents.

Manufacturing barriers

Important execution risks include:

• Hydrochlorothiazide content-uniformity failures.
• Segregation during transfer and compression.
• Losartan impurity growth during stability testing.
• Tablet sticking or capping.
• Coating defects.
• Dissolution failure after scale-up.
• Inconsistent API particle-size distribution.
• Raw-material shortages.
• Nitrosamine and other impurity-control requirements where applicable to the full process and supply chain.

Intellectual-property barriers

Potential residual IP issues include:

• New dosage forms.
• Combination products with additional actives.
• Specific manufacturing processes.
• Device-assisted administration.
• Formulations with unusual stability or dissolution characteristics.
• Country-specific patents.

A standard immediate-release generic tablet is unlikely to justify a large patent budget unless the applicant can demonstrate a nonroutine technical advantage.

What licensing deals are relevant to losartan/hydrochlorothiazide?

The original product was developed and commercialized by Merck. Current opportunities are more likely to involve:

• API supply agreements.
• Contract development and manufacturing agreements.
• Regional commercialization rights.
• Private-label supply.
• Tender partnerships.
• Portfolio acquisitions involving multiple antihypertensive products.

Licensing value is limited for an undifferentiated immediate-release generic. A differentiated formulation, regional registration package, or reliable low-cost API source can support a stronger transaction than a conventional tablet alone.

What generic launch scenarios exist?

Scenario 1: Standard immediate-release generic

This is the lowest-risk path. The manufacturer uses established excipients, develops three principal strengths, and competes on price and supply reliability.

Scenario 2: Cost-reduced platform

The applicant uses direct compression or simplified granulation, a common core formulation, and efficient packaging. The main risk is failure to maintain uniformity and dissolution during commercial scale-up.

Scenario 3: Differentiated patient-use product

An orally disintegrating, sprinkle, or easier-to-swallow version targets a narrower population. The product can potentially obtain better pricing but requires additional development and regulatory work.

Scenario 4: Regional market entry

A company targets countries where losartan/hydrochlorothiazide is approved but generic penetration is low. The commercial thesis depends on local registration, reimbursement, tender access, and API economics.

Key Takeaways

• Losartan potassium and hydrochlorothiazide is a mature generic combination with no biosimilar pathway.
• Core patent protection for losartan, Hyzaar, and the fixed-dose combination is no longer the principal U.S. market barrier.
• The strongest excipient strategy emphasizes content uniformity, moisture control, rapid dissolution, and low manufacturing cost.
• Hydrochlorothiazide distribution is a central formulation risk because it is present at a lower dose than losartan.
• Microcrystalline cellulose, lactose, starches, crospovidone, magnesium stearate, colloidal silicon dioxide, and hypromellose are representative excipient choices, subject to product-specific development.
• Formulation patents are most credible when supported by comparative data showing improved stability, dissolution, uniformity, or manufacturability.
• Commercial opportunities exist in low-cost platforms, lactose-free products, patient-friendly dosage forms, regional supply, and private-label manufacturing.
• The main barriers are operational execution, API supply, stability, and price competition rather than primary patent expiration.
• Standard generic tablets are unlikely to support premium pricing without a clear regulatory, manufacturing, or patient-use advantage.

FAQs

Is losartan potassium and hydrochlorothiazide still protected by patents?

The original compound and fixed-dose combination patents are expired or commercially nonblocking in major generic markets. Product-specific formulation or process patents may differ by jurisdiction.

Can losartan/hydrochlorothiazide be developed as an orally disintegrating tablet?

Yes, but the product would require formulation development focused on taste, dose uniformity, disintegration, stability, and bioequivalence. It would not automatically qualify as a simple conventional-tablet ANDA product.

Which excipient is best for hydrochlorothiazide content uniformity?

No single excipient is universally optimal. A controlled premix, suitable particle-size distribution, and a segregation-resistant process are usually more important than the identity of one excipient.

Is a lactose-free losartan/hydrochlorothiazide product commercially attractive?

It can be attractive for selected markets and patient segments, but the opportunity depends on manufacturing cost, labeling requirements, procurement demand, and whether the alternative formulation maintains dissolution and stability.

What is the highest-value patent strategy for a new losartan/hydrochlorothiazide product?

A patent strategy based on a demonstrated technical effect, such as improved stability, dissolution, content uniformity, or a patient-use advantage, is stronger than a claim covering routine substitution of one filler or lubricant.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Refuse-to-receive standards. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. Center for Drug Evaluation and Research.

4. DailyMed. (2024). Losartan potassium and hydrochlorothiazide tablets: Product labeling. National Library of Medicine.

5. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.